Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cisplatin + Fluorouracil + Tislelizumab|
Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cisplatin||Platinol||CDDP||Chemotherapy - Platinum 6||Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 12||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|Tislelizumab||BGB-A317||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 68||Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||esophagus squamous cell carcinoma||not applicable||Cisplatin + Fluorouracil + Tislelizumab||Phase II||Actionable||In a Phase II trial, Tislelizumab (BGB-A317) in combination with Platinol (cisplatin) and Adrucil (fluorouracil) demonstrated tolerability in patients with advanced esophageal squamous cell carcinoma and resulted in an objective response rate of 46.7% (7/15, all partial responses), disease control rate of 80% (12/15), median time to response of 10.0 weeks, and median progression-free survival of 10.4 months (PMID: 32561664; NCT03469557).||32561664|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03777657||Phase III||Capecitabine + Oxaliplatin Cisplatin + Fluorouracil Capecitabine + Oxaliplatin + Tislelizumab Cisplatin + Fluorouracil + Tislelizumab||Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma||Recruiting||USA||13|